Get the Stockscreener App
0.00
100.00%
-0.0001
Virpax Pharmaceuticals Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
See More
Previous Close:
$0.0001
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
$-12.07M
P/E Ratio:
0.00
EPS:
-10.6183
Net Cash Flow:
$-16.71M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$0.021
Virpax Pharmaceuticals Inc Stock (VRPX) Company Profile
Name
Virpax Pharmaceuticals Inc
Sector
Industry
Phone
-
Address
-
Compare VRPX vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRPX
Virpax Pharmaceuticals Inc
|
0.00 | 0 | 0 | -12.07M | -16.71M | -10.62 |
VRTX
Vertex Pharmaceuticals Inc
|
485.65 | 123.36B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.69 | 71.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
860.55 | 53.68B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
186.16 | 38.09B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
267.47 | 37.80B | 4.29B | 577.22M | 641.34M | 4.2086 |
Virpax Pharmaceuticals Inc Stock (VRPX) Latest News
Form S-1/A Virpax Pharmaceuticals Inc For: 13 July By Investing.com - Investing.com Nigeria
Price to earnings forward of Virpax Pharmaceuticals, Inc. – OTC:VRPX - TradingView
Enterprise value to EBITDA forward of Virpax Pharmaceuticals, Inc. – OTC:VRPX - TradingView
Price to book forward of Virpax Pharmaceuticals, Inc. – OTC:VRPX - TradingView
Price to sales forward of Virpax Pharmaceuticals, Inc. – OTC:VRPX - TradingView
Enterprise value to revenue forward of Virpax Pharmaceuticals, Inc. – OTC:VRPX - TradingView
Virpax Pharmaceuticals, Inc. Actuals & Estimates (OTC:VRPX) - TradingView
Form S-1/A Virpax Pharmaceuticals Inc For: 25 June By Investing.com - Investing.com Nigeria
Top Players and Market Competition in the Non-Opioid Pain Patch Industry - openPR.com
VRPX Stock Plummets 95.5% in Pre-Market Trading on NASDAQ - Meyka
Virpax Pharmaceuticals, Inc. (VRPX) - Minichart
Virpax Pharmaceuticals (VRPX) Expected to Announce Earnings on Tuesday - Defense World
Comparing Virios Therapeutics (NASDAQ:VIRI) & Virpax Pharmaceuticals (NASDAQ:VRPX) - Defense World
VRPX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Petros Pharmaceuticals (NASDAQ:PTPI) versus Virpax Pharmaceuticals (NASDAQ:VRPX) Head-To-Head Contrast - Defense World
Revenue per share of Virpax Pharmaceuticals, Inc. – OTC:VRPX - TradingView
SpyGlass Pharma Closes $172.5 Million IPO - marketscreener.com
Virpax reports positive study results for pain management drug - MSN
SpyGlass Pharma Prices $150 Million IPO - marketscreener.com
Virpax Pharmaceuticals to conduct reverse stock split - Intellectia AI
Virpax Pharmaceuticals director resigns due to compliance - MSN
Virpax Pharmaceuticals Highlights Leadership Contributions at Clinical Trial Conference - MSN
Cybin to Begin Nasdaq Trading Under New Ticker, Plans to Change Name to Helus Pharma - marketscreener.com
Curanex Pharmaceuticals Shares Fall in Nasdaq Debut - marketscreener.com
Vinay Shah Net WorthInsider Trades and Bio as of Apr 21, 2026 - Benzinga
Nasdaq Announces Delisting of Multiple Companies Including NKGen Biotech, Aquaron Acquisition Corp, and Others - Quiver Quantitative
ENSCW Stock Price, News & Analysis - Stock Titan
BTAX Stock Price, News & Analysis - Stock Titan
QBIO Stock Price, News & Analysis - Stock Titan
EVLO Stock Price, News & Analysis - Stock Titan
PXMD Stock Price, News & Analysis - Stock Titan
XSNX Stock Price, News & Analysis - Stock Titan
Virpax Pharmaceuticals stock plummets on Nasdaq delisting news - Investing.com
Virpax Pharmaceuticals enacts 1-for-25 reverse stock split - Investing.com
Virpax Pharmaceuticals announces 1-for-25 reverse stock split By Investing.com - Investing.com UK
Virpax Looking to Use MET to Develop Intranasal COVID Vaccine - FinancialContent
Can Virpax's Nasal Pain Treatment Solve the Opioid Addiction Problem? - Stock Titan
VRPX Soars On MET Results, COLL Projects 16%-19% Revenue Growth In 2025, RPID Gains Momentum - RTTNews
Military Breakthrough: New Pain Control Drug Shows 96-Hour Combat Effectiveness in Army Tests - Stock Titan
Virpax Pharmaceuticals appoints new independent director - MSN
Virpax Pharmaceuticals director resigns due to compliance By Investing.com - Investing.com Nigeria
Virpax's Matthew Barnes to Present at Outsourcing in Clinical Trials Conference - FinancialContent
Virpax Pharmaceuticals Closes of $6.0 Million Public Offering of Common Stock - citybiz
User - The Chronicle-Journal
Virpax Pharmaceuticals granted Nasdaq listing extension - Investing.com
Virpax Pharmaceuticals names new board director - Investing.com
Virpax Pharmaceuticals lowers quorum requirement By Investing.com - Investing.com Nigeria
Capricor Therapeutics (CAPR) Stock Surges Amid Positive Analyst Ratings - GuruFocus
Spartan Capital Securities, LLC Serves as Sole Placement - GlobeNewswire
Star Tribune - FinancialContent
ADM’s multiple accounting errors and SEC probe are ‘highly concerning’ to investors - Fortune
Virpax Pharmaceuticals Inc Stock (VRPX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.80%
2.11%
Cap:
|
Volume (24h):